35260-96-9

Usage

Uses

Used in Pharmaceutical Industry:
2-(1-Ethoxypropylidene)malononitrile is used as an intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
2-(1-ETHOXYPROPYLIDENE)MALONONITRILE is also utilized as an intermediate in the production of agrochemicals, playing a role in the creation of pesticides and other agricultural products to enhance crop protection and yield.
Used in Organic Synthesis:
2-(1-Ethoxypropylidene)malononitrile is employed as a building block in the synthesis of complex organic molecules, facilitating the construction of diverse chemical structures for various applications.
Used in Medicinal Chemistry:
As a reagent, 2-(1-Ethoxypropylidene)malononitrile is instrumental in the preparation of heterocyclic compounds, which are often found in biologically active molecules and pharmaceuticals, thus aiding in the advancement of medicinal chemistry.

InChI:InChI=1/C8H10N2O/c1-3-8(11-4-2)7(5-9)6-10/h3-4H2,1-2H3

Upstream product

• 109-77-3 malononitrile 
• 115-80-0 Triethyl orthopropionate 

Downstream Products

• 35261-00-8 5-amino-3-ethyl-isoxazole-4-carbonitrile 
• 37046-95-0 4-Amino-5-cyano-6-ethyl-2-methylpyrimidine 
• 650628-98-1 5-amino-3-ethyl-1-(3-methoxyphenyl)-1H-pyrazole-4-carbonitrile 
• 91997-08-9 3-Ethyl-4-amino-isoxazolo<5.4-d>pyrimidin 
• 870189-41-6 5-amino-3-ethyl-1-(2-methoxy-phenyl)-1H-pyrazole-4-carbonitrile 
• 1290138-42-9 3-ethyl-5-(ethylamino)-1-(4-methoxyphenyl)-1H-pyrazole-4-carbonitrile 
• 1290138-43-0 3-ethyl-5-(diethylamino)-1-(4-methoxyphenyl)-1H-pyrazole-4-carbonitrile 
• 1290138-44-1 5-(diethylamino)-3-ethyl-1-(4-hydroxyphenyl)-1H-pyrazole-4-carbonitrile 
• 1290137-84-6 (Z)-5-(diethylamino)-3-ethyl-N'-hydroxy-1-(4-hydroxyphenyl)-1H-pyrazole-4-carboximidamide 
• 1290138-41-8 5-amino-1-(4-methoxyphenyl)-3-ethyl-1H-pyrazole-4-carbonitrile 
• 1448812-35-8 N-(3-chloro-5-(((4-cyano-3-ethyl-1-phenyl-1H-pyrazol-5-yl)amino)methyl)-2-hydroxyphenyl)propionamide 
• 870189-49-4 2-[5-ethyl-2-(2-methoxy-phenyl)-4-thiocarbamoyl-2H-pyrazol-3-ylamino]-5-methoxy-benzoic acid methyl ester 
• 870189-43-8 2-[5-ethyl-2-(2-methoxy-phenyl)-4-thiocarbamoyl-2H-pyrazol-3-ylamino]-5-methyl-benzoic acid methyl ester 
• 870189-42-7 C₂₂H₂₂N₄O₃ 

Relevant academic research and scientific papers

Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors

Herein we report the discovery of a series of new small molecule inhibitors of histone lysine demethylase 4D (KDM4D). Molecular docking was first performed to screen for new KDM4D inhibitors from various chemical databases. Two hit compounds were retrieved. Further structural optimization and structure-activity relationship (SAR) analysis were carried out to the more selective one, compound 2, which led to the discovery of several new KDM4D inhibitors. Among them, compound 10r is the most potent one with an IC50 value of 0.41?±?0.03?μM against KDM4D. Overall, compound 10r could be taken as a good lead compound for further studies.

The pyrazole derivative or its salt in a pharmaceutical composition containing them

PROBLEM TO BE SOLVED: To provide a novel compound and a pharmaceutical composition useful for treatment and/or prevention of HIV virus infections.SOLUTION: Provided is a pyrazole derivative represented by the general formula (I) or a salt thereof (in the

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

SUBSTITUTED PYRAZOLES AS ESTROGEN RECEPTOR LIGANDS

The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R4, R5, R6 and R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.

SUBSTITUTED PYRAZOLES AS ESTROGEN RECEPTOR LIGANDS

The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R4, R5, R6 and R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.

PYRIMIDINE DERIVATIVES AND THEIR USE FOR CONTROLLING UNDESIRED PLANT GROWTH

Compounds of the formula (I) and their agrochemically compatible salts and their use in the field of crop protection are described.

PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS

The present invention relates to pyrrole and pyrazole compounds of formula (I) and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression. The compounds act as potentiators on glutamate receptors, in particular AMPA and the GluR family.

5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES

The present invention relates to 5-anilino-4-heteroarylpyrazole compounds, pharmaceutical compositions, and methods for treating diabetes and related disorders.

PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS

The present invention relates generally to inhibitors of the kinases and more particularly to novel pyrazolopyrimidine compounds.

6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof

Novel 6-heterocyclyl-pyrazolo[3,4-d]pyrimidin-4-ones, useful in treating cardiovascular disease, are prepared by reacting a 5-amino-1H-pyrazole-4-carboxamide with heterocyclylcarboxaldehyde or by reacting a 5-amino-1H-pyrazole-4-carbonitrile with a heterocyclylcarboxamidine, followed by diazotization and hydrolysis of the resulting 4-amino-6-heterocyclyl-pyrazolo[3,4-d]pyrimidine.